Table 1.

Fusion proteins of NKG2D/NKG2DLs in cancer immunotherapy.

Strategy	Fusion Protein	Target/Pathway	Malignancy	References
NKG2DL + Antibody	H60-TNT3	UNA	YAC-1	[35,36]
	Rae1β-TNT3	UNA	CT-26, LLC	[36]
	MICAE-Fc (conjugate with Fab)	CEA/HER2/CD20	CC, BC, OC, Raji	[40]
	ULBP2-BB4	CD138	MM	[42]
	anti-HER2 IgG3-Rae1β	HER2	MC	[37]
	ULBP2-anti-PSMA scFv	PSMA	PC	[43]
	MICAE-7D8	CD20	CLL, MZL, MCL	[38]
	ULBP2E-7D8	CD20	CLL, MZL, MCL	[38]
	ULBP2-anti-CEA	CEA	CC	[44]
	mAb04-MICAE	VEGFR	BC	[39]
	anti-VEGFR2 scFv-MICAE	VEGFR	HUVEC, K562, MDA-MB-435	[46]
	rG7S-MICAE	CD24	HCC	[41]
NKG2DL + Cytokine	MULT1E-IL-12	IL-12R	TC-1	[56]
	MICAE-IL-12	IL-12R	A549	[57]
	OMCP-mutIL-2	IL-2R	LLC, YAC-1	[58]
NKG2DL + Fas	MULT1E-FasTI	Fas	TC-1	[67,68]
NKG2D + Antibody	NKG2DE-Fc	ADCC	BC	[69,70]
	Dap10-Fc-NKG2DE	–	RMA/RG, P815	[71]
	anti-CD3 scFv-NKG2DE	CD3	RMA/RG, P815, ID8, MC-38	[73]
NKG2D + Cytokine	NKG2DE-Fc-IL-2	IL-2R	TC-1	[74]
	dsNKG2DE-IL-15	IL-15R	CC	[75]
	dsNKG2DE-IL-21	IL-21R	CT-26	[80]
NKG2D CARs	NKG2D-CD3ζI	TCR	MM, OC, Lymphoma, BC, etc.	[86,87,88,89,90,91,92,93,94,95,96,97,101]
	NKG2DE-CD28-CD3ζI	TCR	ESFT, 4T1.2	[98,101]
	NKG2DE-4-1BB-CD3ζI	TCR/CD137	OC	[99]
	DAP10-NKG2DE-CD3ζI	TCR	Osteosarcoma, 4T1.2	[100,101]

Subscript formatted E, T and I indicate extracellular domain, transmembrane domain, and intercellular domain, respectively. The NKG2D/NKG2DLs pathway was not included in the Target/Pathway column. UNA, universal nuclear antigen; LLC, Lewis lung carcinoma; CEA, carcinoembryonic antigen; HER2, human epidermal growth factor receptor 2; CC, colon carcinoma; BC, breast carcinoma; OC, ovarian carcinoma; MM, multiple myeloma; MC, mammary carcinoma; PSMA, prostate carcinoma membrane; PC, prostate carcinoma; CLL, chronic lymphocytic leukemia; MZL, marginal zone lymphoma; MCL, mantle cell lymphoma; VEGFR, antigen vascular endothelial growth factor receptor; HUVEC, human umbilical vein endothelial cell; HCC, hepatocellular carcinoma; TCR, T cell receptors; ESFT, Ewing’s sarcoma family of tumors.